Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertib
2026-03-09 7:00 AM EDT | Telo Genomics Corp.
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised
Biotechnology, Pharmaceuticals, Health
2026-03-09 3:15 AM EDT | Defence Therapeutics Inc.
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal legislation. As previously annou
Biotechnology, Pharmaceuticals
2026-03-06 5:04 PM EST | InMed Pharmaceuticals
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 4:05 PM EST | Phio Pharmaceuticals Corp.
BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately. Mr. Tsur has served on BioHarvest's Board since 2021 and
Biotechnology, Pharmaceuticals, Health
2026-03-05 7:30 AM EST | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 7:00 AM EST | Phio Pharmaceuticals Corp.
Octane Medical Group Signs Agreement to Acquire Lonza's Personalized Medicine Business
Kingston, Ontario--(Newsfile Corp. - March 4, 2026) - Octane Medical Group ("Octane") today announced that it has entered into a definitive agreement to acquire Lonza's Personalized Medicine business. For Octane, this is a strategically significant deal that comprises Lonza's controlling stake in the Cocoon® Platform - originally acquired from Octane in 2018 - alongside associated intellectual property (IP), workforce and existing customer contracts. Completion of the transact
Biotechnology, Pharmaceuticals
2026-03-04 6:00 PM EST | Octane Medical Group
Marvel Biosciences Sponsors Scientific Meeting on Purines
Calgary, Alberta--(Newsfile Corp. - March 4, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announced it is sponsoring the 3rd European Purine Meeting taking place in Bordeaux, France, from June 30 to July 3, 2026. The 3rd European Puri
2026-03-04 7:00 AM EST | Marvel Biosciences Corp.
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Ontario and Boston, Massachusetts--(Newsfile Corp. - March 4, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced financing transactions totaling $7.1 million, significantly strengthening the Company's balance sheet and financial position. The transactions include:
2026-03-04 7:00 AM EST | Sernova Biotherapeutics
Zenith Capital Corp. Appoints Bryan Ede to Board of Directors
Calgary, Alberta--(Newsfile Corp. - March 3, 2026) - Zenith Capital Corp. ("Zenith" or the "Company") today announces the appointment of Mr. Bryan R. Ede, J.D. as a member of the Company's Board of Directors following the retirement of Dr. Norman Wong, M.D. as a member of the Board. Mr. Ede worked over 27 years in Calgary as a commercial lawyer. He was a national firm Equity Partner for McMillan LLP and Miller Thomson LLP and has extensive law firm management experience as a Calga
2026-03-03 6:15 PM EST | Zenith Capital Corp.
Jeffrey W. Sherman, MD, Joins DIMERx Board to Advance Next-Generation, Non-Addictive Pain Therapies
San Francisco, California--(Newsfile Corp. - March 3, 2026) - DIMERx, Inc. ("DIMERx" or "the Company"), is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug abuse and dependence, with a portfolio of first-in-class, dimer-based pain therapeutics engineered to deliver effective analgesia without the addiction liabilities of conventional opioids. The Company announced the appointment of Jeffrey W. Sherman, MD, FACP, to its Board of Directors. Dr.
Biotechnology, Pharmaceuticals, Health
2026-03-03 9:00 AM EST | DIMERx INC.
Nextleaf Solutions Reports Profitable Q1 FY26 with Revenue Growth and Positive Operating Cash Flow
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor announced today its financial results for the three months ended December 31, 2025 ("Q1 FY26") reporting gross revenue of CAD $3,994,369, net revenue of CAD $3,020,519, and gross profit of CAD $1,288,197. Q1 FY26 marked continued execution, with s
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-03-03 8:59 AM EST | Nextleaf Solutions Ltd.
BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 38th Annual Roth Conference taking place on March 22-24, 2026.
Biotechnology, Pharmaceuticals, Health
2026-03-03 8:30 AM EST | BioHarvest Sciences Inc.
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of psychedelics and peptides, today announced a strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market, building on the Company's ketamine and psychedelics patch development achievements a
Biotechnology, Pharmaceuticals
2026-03-03 8:00 AM EST | PharmaTher Holdings Ltd.
Restart Life Announces Collaboration with University of Manitoba's Centre for Food Technology and Research
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that, following the successful acquisition of Holy Crap Foods Inc., it has entered into a collaboration with the University of Manitoba's Richardson Centre for Food Technology and Research (RCFTR) to support a series of food-related scientific studies that will guide the Company's product development road
Technology, Biotechnology, Health
2026-03-03 6:00 AM EST | Restart Life Sciences Corp.
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Toronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that recent in vitro data demonstrates an enhanced bladder cancer cell kill, when light-activated Ruvidar®
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-03-02 7:00 AM EST | Theralase Technologies Inc.
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026. These high-profile meetings will provide Defence with multiple opportunities to advance strategic p
Biotechnology, Pharmaceuticals, Health
2026-03-02 3:15 AM EST | Defence Therapeutics Inc.
Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to
2026-02-27 5:21 PM EST | Sharp Therapeutics Corp.
Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the "Private Placement") of up to 20,000,000 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of up to $11,000,000. Each Unit will be compris
Biotechnology, Pharmaceuticals, Health
2026-02-27 5:00 PM EST | Defence Therapeutics Inc.
Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has increased the size of its previously announced non-brokered private placement of non-transferable secured convertible debentures (the "Debentures") from u
2026-02-27 3:32 PM EST | Telo Genomics Corp.